Completed PHASE1 INTERVENTIONAL 3-arm NCT02044367

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study)

Sponsor: Boehringer Ingelheim

Conditions Healthy

Interventions Dabigatran etexilate

Updated 7 times since 2017 Last updated: May 1, 2015 Started: Jan 31, 2014 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02044367, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Biberach, Germany